evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,447 questions · 2,590 findings · 266 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 699 · 27%GRADE not reported 289 · 11.2%Very low 614 · 23.7%Low 605 · 23.4%Moderate 322 · 12.4%High 61 · 2.4%

Belimumab 10 mg/kg vs placebo

Reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks SELENA‐SLEDAI score, a validated marker of SLE disease activity (range 0 to 105; higher score = worse disease activity) · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg leads to higher reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks… compared with placebo (high certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36 PCS score from baseline ( · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg probably leads to higher change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36… compared with placebo (moderate certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Reduction of glucocorticoid dose by at least 50% · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg leads to higher reduction of glucocorticoid dose by at least 50% compared with placebo (high certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in participants with one or more serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Participants with one or more serious infections · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in participants with one or more serious infections compared with placebo (moderate certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Withdrawals due to adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Number of participants who died during the study · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in number of participants who died during the study compared with placebo (low certainty).

1 finding from 1 review

Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol

Number of participants reporting an adverse event · health problem or population

It is very uncertain whether summary of Findings Table ‐ Ibuprofen 300 mg changes number of participants reporting or experiencing any adverse event compared with active comparator (acetaminophen) (very low certainty).

1 finding from 1 review

Summary of Findings Table ‐ Ibuprofen 300 mg vs paracetamol

At least 50% reduction in pain · health problem or population

It is very uncertain whether summary of Findings Table ‐ Ibuprofen 300 mg changes number of participants with at least 50% pain relief at 4 hours compared with active comparator (acetaminophen) (very low certainty).

2 findings from 1 review